Tcr2 Therapeutics Stock EBITDA
Tcr2 Therapeutics fundamentals help investors to digest information that contributes to Tcr2 Therapeutics' financial success or failures. It also enables traders to predict the movement of Tcr2 Stock. The fundamental analysis module provides a way to measure Tcr2 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tcr2 Therapeutics stock.
Tcr2 |
Tcr2 Therapeutics Company EBITDA Analysis
Tcr2 Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Tcr2 Therapeutics EBITDA | (89.62 M) |
Most of Tcr2 Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tcr2 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Tcr2 Therapeutics reported earnings before interest,tax, depreciation and amortization of (89.62 Million). This is 110.21% lower than that of the Biotechnology sector and 189.48% lower than that of the Health Care industry. The ebitda for all United States stocks is 102.3% higher than that of the company.
Tcr2 EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tcr2 Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tcr2 Therapeutics could also be used in its relative valuation, which is a method of valuing Tcr2 Therapeutics by comparing valuation metrics of similar companies.Tcr2 Therapeutics is currently under evaluation in ebitda category among its peers.
Tcr2 Fundamentals
Return On Equity | -0.91 | |||
Return On Asset | -0.35 | |||
Current Valuation | (73.69 M) | |||
Shares Outstanding | 39.26 M | |||
Shares Owned By Insiders | 1.50 % | |||
Shares Owned By Institutions | 54.31 % | |||
Number Of Shares Shorted | 360.89 K | |||
Price To Book | 0.22 X | |||
EBITDA | (89.62 M) | |||
Net Income | (151.82 M) | |||
Cash And Equivalents | 175.99 M | |||
Cash Per Share | 4.55 X | |||
Total Debt | 58.23 M | |||
Debt To Equity | 0.29 % | |||
Current Ratio | 5.02 X | |||
Book Value Per Share | 2.58 X | |||
Cash Flow From Operations | (101.46 M) | |||
Short Ratio | 1.29 X | |||
Earnings Per Share | (4.20) X | |||
Target Price | 6.43 | |||
Number Of Employees | 58 | |||
Beta | 1.93 | |||
Market Capitalization | 58.11 M | |||
Total Asset | 208.24 M | |||
Retained Earnings | (501.34 M) | |||
Working Capital | 113.56 M | |||
Z Score | -3.54 | |||
Net Asset | 208.24 M |
Pair Trading with Tcr2 Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |